Sep 7, 2026 · 21 min · 7 segments
In this milestone tenth episode of Bench to Boardroom, we explore how life sciences companies can build a resilient growth engine capable of creating value even when geopolitics, pricing policy…
Not long ago, many Western pharmaceutical companies principally viewed China as a large commercial market, manufacturing base, or source of development efficiency.
That framing is now badly outdated.
In 2025, 40% of all assets in-licensed by Big Pharma had a Chinese licensor, up from just under 30% in 2024. the aggregate value of therapeutic licensing deals involving Chinese-originated assets more than doubled from approximately 45 billion in 2024 to 105 billion in 2025.
And by the end of the first half of 2026, those deals had already reached approximately 92 billion.
88% of the entire 2025 total.
Another estimate puts first half 2026 Chinese innovative drug out licensing at approximately 110 billion.
Different methodologies produce different totals, but the direction is unmistakable.
More than 30% of assets in global antibody and cell therapy pipelines now originate in China.
And Chinese-originated assets account for more than 40% of the top 20 biopharma companies' 2025 deal expenditures in its analysis.
And this is not simply oncology anymore.
In 2025, oncology represented 49% of China to big pharma licensing deal count, but immunology represented 22% and cardiovascular, renal and metabolic disease, another 20%.
And nor are these token transactions.
AstraZeneca's 2026 CSBC collaboration spans eight programs and carries potential value of $18.5 billion.
Pfizer's InnoVent transaction covers 12 oncology programs and up to 10.5 billion in potential consideration.
These are increasingly portfolio transactions, not opportunistic asset shopping.
So there is an important strategic shift underway.
Global innovation sourcing is no longer optional diversification.
It is becoming a core capability.
But globalization creates a paradox.
Here's what makes this interesting.
The science is becoming more global precisely as the operating environment becomes more fragmented.
Not long ago, many Western pharmaceutical companies principally viewed China as a large commercial market, manufacturing base, or source of development efficiency.
That framing is now badly outdated.
In 2025, 40% of all assets in-licensed by Big Pharma had a Chinese licensor, up from just under 30% in 2024. the aggregate value of therapeutic licensing deals involving Chinese-originated assets more than doubled from approximately 45 billion in 2024 to 105 billion in 2025.
And by the end of the first half of 2026, those deals had already reached approximately 92 billion.
88% of the entire 2025 total.
Another estimate puts first half 2026 Chinese innovative drug out licensing at approximately 110 billion.
Different methodologies produce different totals, but the direction is unmistakable.
More than 30% of assets in global antibody and cell therapy pipelines now originate in China.
And Chinese-originated assets account for more than 40% of the top 20 biopharma companies' 2025 deal expenditures in its analysis.
And this is not simply oncology anymore.
In 2025, oncology represented 49% of China to big pharma licensing deal count, but immunology represented 22% and cardiovascular, renal and metabolic disease, another 20%.
And nor are these token transactions.
AstraZeneca's 2026 CSBC collaboration spans eight programs and carries potential value of $18.5 billion.
Pfizer's InnoVent transaction covers 12 oncology programs and up to 10.5 billion in potential consideration.
These are increasingly portfolio transactions, not opportunistic asset shopping.
So there is an important strategic shift underway.
Global innovation sourcing is no longer optional diversification.
It is becoming a core capability.
But globalization creates a paradox.
Here's what makes this interesting.
The science is becoming more global precisely as the operating environment becomes more fragmented.
The rest of this transcript — segmented and speaker-labeled, so you land on the exact moment something was said
Search every transcript — by keyword, by phrase, or by meaning, across every show Radar indexes
Trends — what is surging across podcasts, measured against its own baseline
Alerts — when a name you follow appears in a newly indexed episode
No account is needed to search Radar.
